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ABSTRACT
The clinical deployment of immune checkpoint inhibitors (ICIs) has created a 
tandem drive for the identification of biomarkers linked to benefit. Comprehensive 
genomic profiling was performed to evaluate the frequency of genomic biomarkers of 
ICI response in 755 patients with advanced hepatocellular carcinoma (HCC). Median 
age was 62 years’ old, 73% were male, 46% had extrahepatic disease, 107 had 
documented hepatitis C, 96 had hepatitis B and 4 patients were coinfected. Median 
tumor mutation burden (TMB) was 4 mutations/Mb and only 6 tumors (0.8%) were 
TMB-high. Out of 542 cases assessed for microsatellite instability (MSI), one (0.2%) 
was MSI-high and TMB-high. Twenty-seven (4%) patients had POLE/D alterations. 
One patient had a pathogenic POLE R762W mutation but TMB was 4 mutations/Mb. 
Forty percent had DNA damage response gene alterations. In a small case series 
(N=17) exploring the relationship between biomarkers and ICI response, one patient 
(TMB 15 mutations/Mb, MSI-low) had a sustained complete response to nivolumab 
lasting > 2 years. Otherwise there were no significant genomic or TMB differences 
between responders, progressors, and those with stable disease. Overall, markers of 
genomic instability were infrequent in this cohort. Larger clinically annotated datasets 
are needed to explore genomic and non-genomic determinants of ICI response in HCC. 
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INTRODUCTION
Virally associated cancers like hepatocellular 
carcinoma (HCC) illustrate the disrupted balance between 
immune system attack and regulation [1]. The immune 
checkpoints PD-1 and CTLA-4 are activated in the 
presence of a chronic infection to suppress cytotoxic T 
cells and prevent immune-mediated host tissue damage. 
Cancer cells commandeer and manipulate these regulatory 
signals to escape immune surveillance, resulting in 
unimpeded growth and metastasis. The concept of 
harnessing the immune system to attack cancer cells 
has been actualized with the development of immune 
checkpoint inhibitors (ICIs) which restore effector T cell 
function and cell mediated cytotoxicity. PD-1 inhibitors 
have shown activity across multiple solid and hematologic 
malignancies including HCC. Based on the results of the 
phase I/II CheckMate 040 and phase II KEYNOTE-224 
trials [2, 3], nivolumab and pembrolizumab have been 
FDA approved for HCC after progression on sorafenib. 
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Additional trials expanding the use of ICIs in HCC in 
earlier treatment contexts are underway, with the results 
of the phase III CheckMate 459 trial of sorafenib vs 
nivolumab in first-line eagerly anticipated.
Responses to ICIs occur in a limited subset of 
patients across most cancer types including HCC [4]. 
An unmet need exists to develop predictive biomarkers 
to identify individuals most likely to respond to 
immunotherapies. PD-1 ligand (i.e. PD-L1) expression 
is an FDA approved companion biomarker used to select 
patients with esophagogastric adenocarcinoma or non-
small cell lung cancer suitable for treatment with PD-1 
inhibitors. Mismatch repair protein (MMR) deficiency or 
microsatellite instability (MSI) is also an FDA approved 
indication for the use of PD-1 inhibitors in advanced solid 
tumors given the strikingly higher response rates observed 
in MMR deficient/MSI-high compared to MMR proficient 
or MSI-low tumors [5]. Other emerging biomarkers 
include tumor mutation burden (TMB), alterations in DNA 
damage response (DDR) genes and DNA polymerases 
epsilon and delta (POLE and POLD), among others. 
Owing to historically lower biopsy rates and poor 
outcomes, few studies have examined the landscape of 
putative immunotherapy biomarkers in advanced HCC. 
In this study, we survey the genomic landscape of 755 
HCC specimens to identify patterns and associations with 
current as well as emerging biomarkers of response to 
PD-1 inhibitors. We also include a case series of patients 
with advanced HCC who received PD-1 inhibitors and 
evaluate their genomic profiles in the context of their 
responses to these agents.
RESULTS
Patient characteristics
The median age of diagnosis was 62 years old (range 
19-91 years). Female and male patients were 27% and 
73% percent, respectively. Hepatitis B (HBV) infection 
was determined by chart review (96 noted/suggested 
HBV+), of which 84 were also HBV+ by sequencing. 
Chart review identified 111 patients with hepatitis C (HCV, 
4 co-infected with HBV). Seven patients had nonalcoholic 
steatohepatitis (NASH), 1 had a history of alcoholic liver 
disease, and 54 had cirrhosis of undocumented etiology. 
Nearly half (47%) had documented metastastic disease, 
with the most common sites of metastases being lung 
(8%), bone (6%), abdominopelvic soft tissue (6%), lymph 
nodes (4%) and adrenal gland (2%). Patient characteristics 
are summarized in Table 1.
Mutational landscape of HCC
Known or likely pathogenic mutations were 
identified in 751 cases; the other 4 cases only had variants 
of unknown significance (VUS). The most commonly 
altered genes were TERT (44%), TP53 (35%), CTNNB1 
(31%), ARID1A (12%), and MYC (12%). All MYC 
alterations were amplifications. Mutations in CDKN2A, 
RB1, ARID2, MCL1, and PTEN occurred in 5-8% of 
specimens. Other alterations found at low rates that might 
be relevant for targeted therapies included NTRK1 (2%), 
several PI3 kinase pathway genes (TSC2, AKT3, STK11), 
and MET (2–4%). No appreciable differences between 
the mutational profiles of primary HCCs and metastatic 
lesions were noted (data not shown). All alterations with a 
frequency >5% are shown in Figure 1. 
Tumor mutation burden (TMB), microsatellite 
status and PD-L1 expression
The median TMB for the entire cohort was 4 
mutations/Mb, with 95% of cases having a TMB of 
< 10 mutations/Mb. Gender, HBV or HCV status, 
age and the proportion of primary vs metastatic 
tumors did not differ significantly amongst TMB 
subgroups (Table 2). Microsatellite status was 
determined in 542 specimens; only one was both 
MSI-high and TMB high (21 mutations/Mb). 
This specimen belonged to an 82 years’ old Caucasian 
male with unknown risk factors or cirrhosis status. Three 
(50%) tumors were MSI-low in the TMB-high group, 
128 (68%) in the TMB intermediate and 411 (73%) in 
the TMB-low group (p > 0.05). Microsatellite status was 
ambiguous (ie. not MSI-low but below the MSI-high 
cutoff) in 4 specimens and not evaluable in 209 specimens.
PD-L1 expression levels were only available for 
65 patients: 32 had “low positive”, 3 had “high positive” 
scores, and 29 were PD-L1 negative. PD-L1 positivity was 
not associated with high TMB; the 3 patients with high 
positive PD-L1 were TMB low (2-5 mutations/Mb). Gene 
alteration frequencies in PD-L1 positive tumors are shown 
in Figure 1.
Differences in mutation profile amongst TMB 
subgroups were analyzed. Though TMB-high HCCs 
demonstrated some genetic differences compared to 
TMB-intermediate and low HCCs, their numbers were too 
small (N=6) to be conclusive. No significant differences 
emerged between TMB low and intermediate HCCs 
(Figure 2). 
Since 90% of specimens had a TMB of <10 
mutations/Mb, we explored potential genetic differences 
using modified TMB cutoffs: TMB <4 mutations/Mb 
(N = 476), 5-9 mutations/Mb (N = 227), > 10 mutations/
Mb (N = 52). The pattern and frequency of alterations 
associated with the new subgroups generally mirrored 
those observed with the original subgroups. Gene 
alterations that significantly differed between at least 2 of 
the new TMB subgroups are shown (Figure 3). 
POLE and D mutations
Alterations in the proofreading domains of POLE 
and POLD were detected in 27 of 755 specimens (4%): 
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18 male and 9 female patients. A Caucasian male, 64 
years’ old with cirrhosis, TMB 4 mutations/Mb and 
MSI-low had a pathogenic POLE R762W mutation. The 
other 26 patients had POLE/D VUS. Median TMB of 
all patients with POLE/D variants was 5 mutations/Mb 
with no statistically significant difference in POLE/D 
mutation frequency by etiology: 1/7 (14%) in patients 
with NASH, 2/96(2%) in patients with HBV including 
4 coinfected with HCV and 6/107 (6%) in patients with 
HCV only. 
Table 1: Characteristics of study population and biomarker subgroups
Patient characteristics
Biomarker subgroups
Total 
N = 755
PD-L1+
N = 35
POLE/D
N = 27
DDR
N = 306
Median age (range) 62 (19-91) 65 67 62
% Female:male 27:73 29:71 33:67 27:73
Known etiology (N = 269)
 Hepatitis B
 Hepatitis C 
 NASH
 Alcohol
 Cirrhosis etiology unknown
96
111* 
7
1
54
2
9
3
2
7
1
2
37
42
4
12
Known site of tissue tested 
 Liver 
 Lymph nodes
 Lung
 Bone
 Abdominopelvic soft tissue
 Adrenal gland
 Other
513 (68%)
30 (4%)
60 (8%)
45 (6%)
45 (6%)
15 (2%)
47 (6%)
13 (37%)
5
1
2
2
2
1 gallbladder
15 (55%)
8
3
2
1
1 ovary
144 (47%)
51
14
28
21
18
4
4 brain, 1 ovary, 1kidney, 
1 colon, 
1 pancreas
*4 coinfected with Hepatitis B.
Figure 1: Mutational landscape of HCC across study cohort and biomarker subgroups.
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Figure 2: Differences in gene alteration frequencies by TMB level.
Figure 3: Differences in gene alteration frequencies using modified TMB cutoffs (all genes shown have statistically 
significant differences between 2 or 3 groups).
Table 2: Tumor mutation burden (TMB) distribution by etiology
TMB high TMB intermediate TMB low All
N (%) 6 (1%) 188 (25%) 561 (74%) 755
% Male:Female 67:33 75:25 72:28 73:27
Median age 58 years 63 years 61 years 62 years
Specimen site
Primary liver/not noted
Metastasis
2 (33%)
4 (67%)
94 (50%)
94 (50%)
252 (45%)
309 (55%)
348
407
Liver disease etiology
HCV (no HBV)
HBV (± HCV)
NASH
0
0
0
27 (25%)
31 (32%)
1(14%)
80 (75%)
65 (68%)
6 (86%)
107
96
7
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DNA damage response (DDR) genes
Genomic analysis included 31 genes involved in 
various DNA repair pathways such as POLE/D, BRCA 
1/2, and ATM (Supplementary Table 1). Forty percent 
(N = 306) of 755 specimens contained DDR gene 
alterations including both pathogenic variants and VUS: 
240 had one alteration, 47 had 2 alterations, 17 had 3 
alterations, and 1 patient each had 4 and 5 alterations. 
Non DDR-altered HCCs had a significantly higher 
frequency of mutations in the MYC oncogene (14% 
vs. 9%, P = 0.05) and KEAP1, a regulator of oxidative 
stress and inflammation (4% vs. 1%, P = 0.02) [6]. DDR-
altered tumors had non-significantly higher frequencies of 
mutations in SPTA1 which encodes a molecular scaffold 
protein, cell cycle and intracellular signaling regulators 
CDKN1B and IRS2 and the transcriptional regulator gene 
NCOR1 (all 3% vs 1% in non DDR-altered tumors). TMB 
was not significantly different between DDR-altered and 
unaltered tumors. Furthermore, there were no significant 
differences in mutation profile or TMB levels between 
homologous recombination repair and DNA MMR 
pathways. Loss of heterozygosity (LOH) was evaluated 
as a possible mitigating factor, but fewer than 0.5% of 
patients exhibited LOH and no pattern with respect to any 
of the other parameters was identified (data not shown).
Gene alteration frequencies in tumors with POLE/D 
and DDR alterations are shown in Figure 1.
Case series
Clinical data were available on 17 patients 
with advanced HCC who received a PD-1 inhibitor 
(Supplementary Table 2). Twelve patients were male 
and 10 were >65 years’ old. Four patients were African-
American, 6 were Asian, 3 were Caucasian and 4 were 
Hispanic. Seven patients had an objective response 
including one complete response, 6 had disease 
progression, 3 patients had stable disease and one patient 
discontinued treatment due to toxicity before response 
could be assessed. Eight patients were TMB-intermediate 
(6-15 mutations/Mb) and 9 were TMB-low (1-5 mutations/
Mb). Sixteen cases were evaluable for microsatellite 
status; all were MSI-low. 
The patient who had a durable (>2 year) complete 
response had a history of HCV and the highest TMB of 
all patients in the series (15 mutations/Mb). Overall, TMB 
levels did not segregate by response; 3 TMB-low patients 
responded to nivolumab, and 2 with TMB-high tumors 
had primary progression. One patient (#6) with TMB-
intermediate disease received one dose of nivolumab and 
subsequently developed sepsis secondary to a hepatic 
abscess. Nivolumab was discontinued and the patient 
enrolled in hospice but was discharged 4 months later 
due to a sustained improvement in his clinical condition. 
Repeat imaging indicated that he had, in fact, responded to 
nivolumab, and that the abscess might have developed in the 
context of tumor necrosis. Nivolumab was resumed for one 
dose but soon after he developed rapid disease progression 
and died one month later. Nine patients had DDR alterations: 
6 patients who had a partial response or stable disease each 
had 1-2 alterations, 2 patients each with 2 variants had 
disease progression, and one patient with 4 variants received 
a single dose of nivolumab but was hospitalized for hepatic 
decompensation and discontinued treatment before response 
assessment. No patients had POLE/D alterations. 
DISCUSSION
Immune checkpoint inhibitors have revolutionized 
oncology treatment paradigms, but the high cost and 
potential for serious, albeit rare, adverse events with these 
agents demand judicious patient selection. Immunotherapy 
biomarker development has therefore become a research 
priority. Although PD-L1 expression is an FDA approved 
biomarker, its shortcomings including assay heterogeneity, 
variations in interpretation, and limited sensitivity 
for detecting responders [7, 8] has shifted attention 
to the concept of genomic instability as a predictor of 
susceptibility to PD-1 inhibitors. 
The study population characteristics were 
reflective of the typical HCC patient profile with respect 
to gender ratio, age and sites of metastases. As clinical 
information was not available for most patients, risk 
factors were ascribed in only ~25% of cases, most of 
whom had viral hepatitis. The frequency and spectrum 
of genetic alterations in this cohort were consistent with 
prior series and expand on the genes interrogated more 
comprehensively [9–11].
Markers of genomic instability were generally 
infrequent in this cohort. Only one out of 542 evaluable 
specimens was MSI-high. In a recent series of 122 HCCs 
associated with a variety of etiologies and assessed using 
the gold standard pentaplex PCR technique, no tumors 
were MSI-high, but 26% exhibited lower levels of MSI 
[12]. Low level MSI tended to be more frequent in patients 
with cirrhosis, possibly reflecting genomic instability 
induced by chronic inflammation. In this series, 4 patients 
(0.7%) were microsatellite ambiguous (neither MSI-low 
nor MSI-high).
High nonsynonymous TMB is hypothesized to 
generate increased neoantigen expression by cancer cells 
[13], marking them as targets for an immune system 
activated by immune checkpoint inhibition. While 
increasing TMB correlates with higher response rates 
to PD-1 inhibitors [14–17], only 55% of the differences 
observed across tumor types are attributable to TMB 
[15], indicating that other factors may influence response 
to these agents [8]. Studies in metastatic melanoma and 
non-small cell lung cancer have also shown that TMB 
values in responders and nonresponders frequently overlap 
[14, 16]. Indeed, within our case series, TMB levels ranged 
from 3–15 mutations/Mb in patients who responded or had 
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stable disease, and from 4–9 mutations/Mb among those 
who progressed. 
Although the availability of targeted next generation 
sequencing cancer gene panels has made TMB assessment 
more accessible and demonstrates comparable accuracy to 
whole exome sequencing [16, 18, 19], the application of 
TMB to clinical practice remains challenging. Currently 
no standardized gene platform exists to calculate TMB, 
definitions vary across studies, and tumor heterogeneity 
may result in TMB estimates that do not reflect the global 
TMB landscape within a tumor or across the total disease 
burden of a patient [20]. Furthermore, TMB ranges vary 
across tumor types [18], suggesting that disease specific 
TMB definitions should be explored. One might also 
speculate as to whether HCC TMB differs by type and 
number of risk factors (ie. HCV infection only vs HCV 
and alcohol). In this series, no discernable difference in 
TMB between HCV and HBV infected patients appeared. 
The genetic profile of a tumor may also help to 
distinguish responders from nonresponders. In a study 
of pembrolizumab in non-small lung cancer, a “smoking 
signature” characteristic of tobacco-induced mutagenesis 
correlated with efficacy [21]. In this case series, there were 
no emergent genetic signals distinguishing responders 
from nonresponders due to the small number of patients.
POLE/D mutations appear to define a subset of 
cancers with an ultra-mutated phenotype that are often 
MSI-low and have been linked with durable responses to 
PD-1 inhibition in multiple tumor types [22, 23]. Within 
our study cohort, only one patient had a pathogenic POLE 
R762W mutation previously identified in colorectal cancer 
affecting the catalytic domain of the enzyme [24]. Notably, 
this patient had a TMB of only 4 mutations/Mb. The 
remaining patients evaluable for POLE/D alterations had 
VUS which, based on the low median TMB for the entire 
group, suggests that these variants were not associated 
with clinically meaningful changes in enzyme function.
Recently, DDR alterations have also been associated 
with an increased TMB, tumor lymphocytic infiltration 
and response to PD-1 inhibition [25]. In a retrospective 
series of metastatic urothelial cancers, the presence of 
DDR alterations, especially known pathogenic alterations, 
was independently associated with improved clinical 
outcomes on PD-1/PD-L1 inhibitors [25]. DDR alterations 
were prevalent in this cohort of HCCs and in our case 
series, both responders and nonresponders had >1 DDR 
alteration.
The process of biomarker discovery for 
immunotherapeutic agents is rapidly evolving. It is 
increasingly recognized that complex interactions 
between genetic, microenvironmental and systemic factors 
determine response or lack of response to these agents. 
Existing biomarkers appear to identify small, partially 
overlapping and/or complementary patient subgroups 
that, collectively, may cast a more inclusive net to identify 
treatment candidates. It is plausible to conceive of an 
immunotherapy response prediction matrix consisting of 
TMB, genomic profile, cell surface protein expression 
and other emerging blood, stromal and even stool-based 
markers [26, 27] to facilitate patient selection in the future. 
The main weakness of this study is the lack of 
clinical outcomes information for most patients precluding 
a more in-depth analysis of the relationships between 
specific biomarkers and response to PD-1 inhibition. 
Tumor specimens were heterogeneous with respect to site 
of origin and timing of procurement. The extent to which 
tumor genomic profiles were modified by prior treatments 
cannot be accounted for given the lack of clinical data. 
However, the consistency of our genomic profiling data 
with other studies [9–11] is reassuring. 
In conclusion, this is the first study, to our 
knowledge, to evaluate the pattern and frequency 
of current and emerging biomarkers of response to 
PD-1 inhibitors in HCC. Gene alterations linked with 
hypermutability are infrequent in advanced HCC, and 
the apparent absence of an association between TMB and 
response to PD-1 inhibition suggests that future biomarker 
development in this context may need to look beyond 
markers of genomic instability. A follow-up study with 
clinical outcomes data is warranted to further elucidate 
determinants of response to PD-1 inhibitors in this disease.
MATERIALS AND METHODS
Comprehensive genomic profiling (CGP) of 315 
cancer-related genes was performed on 755 consecutive 
cases of hepatocellular carcinoma (2012-17) using 
a validated hybrid-capture, adaptor ligation based 
NGS assay (FoundationOne®) (Foundation Medicine, 
Cambridge, MA, USA; CLIA certified, CAP-accredited, 
NY State-approved laboratory). Pathologic diagnosis 
of each case was confirmed on routine hematoxylin and 
eosin-stained slides. A 20% minimum tumor nuclei content 
was required for DNA extraction, and genomic alterations 
(GA: point mutations, indels, copy number changes and 
rearrangements) were recorded (median coverage depth of 
743x). Sequence analysis included hepatitis B (HBV) viral 
sequence reference genome alignment. Pathology reports 
were reviewed for documentation of HBV or hepatitis C 
(HCV). TMB was calculated from up to 1.1 megabase 
(Mb) of cancer genome as the number of somatic, coding 
point mutations and indels per Mb (low: <6; intermediate: 
6-19; high: ≥20 mutations/Mb). Microsatellite status 
was determined by a novel algorithm analyzing length 
variability of 114 specific homopolymer repeat loci and 
was evaluable in 542 of the 755 patients’ tissues. PD-L1 
immunostaining of 5 micron thick FFPE tissue sections 
was performed on the Dako Autostainer Link 48 platform 
and an automated staining protocol validated for the 
monoclonal mouse anti-human PD-L1 antibody, clone 
22C3 pharmDx assay. Positive staining was defined as 
complete circumferential or partial cell membrane staining 
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of viable tumor cells. Scoring was recorded as percentage 
of PD-L1-positive tumor cells of the total tumor cells 
evaluated (TPS). The specimen was considered to have 
PD-L1 expression if TPS ≥1% and high PD-L1 expression 
if TPS ≥50% [28]. Only 65 of 755 patients had PD-L1 
testing performed or documented. Approval for this 
study, including a waiver of informed consent and HIPAA 
waiver of authorization, was obtained from the Western 
Institutional Review Board (Protocol 20152817).
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